441
Participants
Start Date
April 22, 2011
Primary Completion Date
May 31, 2015
Study Completion Date
September 8, 2015
EC145
IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
placebo
IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
EC20
During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
Lead Sponsor
Endocyte
INDUSTRY